Recent approvals of gene therapies and cell-based therapies have opened new avenues for biotech companies to create marketable products.

In the medical field, Deep Research can help doctors quickly find relevant literature and clinical trials, saving them time and improving patient care.

Deep Research allows users to generate comprehensive reports on topics of interest, significantly enhancing their learning experience.

Focusing on biopharma companies as a target market allows for a more tailored data solution that meets their specific needs.

We aim to create a general drug design engine with AI that can be applied across various disease areas, not just targeting a single indication.

Access to capital and FDA's development strategies for rare diseases have enabled small biotech companies to bring products to market without being acquired.

The focus for biotech companies is on de-risking their technology by obtaining experimental data and developing a viable therapeutic intervention, which is crucial before entering clinical trials.

There's a significant opportunity in generating in vivo data, which is currently limited, to better understand drug interactions in real biological systems, and we're seeing breakthroughs in data-generating technology in biology and chemistry that will significantly impact how we model these fields.

The biotech industry is experiencing a surge in startups due to unprecedented access to capital and advancements in therapeutic modalities.